ArticleDiscover oncology2025
A systems biology approach to identify key targets in KRAS/BRAF-mutated colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of key genes and pathways involved in trastuzumab resistance in HER2-positive gastric cancer through integrative bioinformatics analysis.Iranian journal of basic medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKRAS and BRAF mutations are critical oncogenic drivers in colorectal cancer (CRC), with distinct molecular and clinical implications.
methodsTo uncover genes differentially expressed between these mutations, we compared KRAS G12D- and BRAF V600E-mutated CRC cell lines. Protein-protein interaction (PPI) network construction, pathway enrichment, survival analysis, and drug target screening were performed to identify therapeutic opportunities.
resultsTen hub genes-TNF, IL1B, FN1, EGF, IFI44L, EPSTI1, AHR, COL20A1, CDH1, and SOX9-were identified as critical in KRAS-driven CRC. Enrichment analysis highlighted immune and inflammatory pathways, including "SARS-CoV-2 Signaling" and "Macrophage Stimulating Protein Signaling," as well as cellular processes like "Positive Regulation of PI3K Signaling". IL1B was the only hub gene significantly associated with overall survival, suggesting its role as a favorable prognostic marker. Drug screening identified selective inhibitors such as Canakinumab and Rilonacept targeting IL1B, with docking studies revealing the strongest interaction for Omeprazole with AHR, followed by Tapinarof with AHR and Donepezil with IL1B.
conclusionsThis study sheds light on the molecular mechanisms of KRAS-mutated CRC, emphasizing IL1B as a prognostic marker. Among the identified therapeutic agents, Omeprazole demonstrated the strongest interaction with AHR, suggesting a potential for repurposing in CRC treatment, while IL1B-targeting inhibitors such as Canakinumab emerged as selective candidates for modulating tumor-promoting inflammation. Novel genes such as EPSTI1, COL20A1, CDH1, and SOX9 warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.